Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Turner, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Turner, P. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 46, 9-23
© 2000 The British Society for Antimicrobial Chemotherapy

MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): a global overview

P. J. Turner*

Antibiotic Development and Technical Support Group, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK

The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) is a global, multicentre surveillance study that compares the activity of meropenem in centres that are prescribers with that of imipenem, ceftazidime, piperacillin/tazobactam, ciprofloxacin and gentamicin. Of the 46 centres (intensive care units, cystic fibrosis units, neutropenia units and general wards) contributing to this study, 29 were in Europe, 14 in the Americas and three in the Middle East and Asia. The results for the most common isolates obtained in the first year of the study from these three regions show that meropenem has a broad spectrum of activity and potency in these centres, with 89% of the 6890 strains tested having an MIC 4 mg/L. The overall susceptibility was lower for the comparator antibiotics. There was evidence in all regions of strains producing ß-lactamases and other resistance mechanisms against the other ß-lactams tested, fluoroquinolones and aminoglycosides. Future years' results from this surveillance study will show whether meropenem will continue to exhibit such activity.

* Corresponding author. Tel: +44-1625-515190; Fax: +44-1625-517436; E-mail: philip.turner{at}astrazeneca.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
J. A. Patzer, D. Dzierzanowska, and P. J. Turner
Trends in antimicrobial susceptibility of Gram-negative isolates from a paediatric intensive care unit in Warsaw: results from the MYSTIC programme (1997-2007)
J. Antimicrob. Chemother., August 1, 2008; 62(2): 369 - 375.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
T. P. Lodise, R. Nau, M. Kinzig, G. L. Drusano, R. N. Jones, and F. Sorgel
Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation
J. Antimicrob. Chemother., November 1, 2007; 60(5): 1038 - 1044.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
G. Kahlmeter and P. Menday
Cross-resistance and associated resistance in 2478 Escherichia coli isolates from the Pan-European ECO{middle dot}SENS Project surveying the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections
J. Antimicrob. Chemother., July 1, 2003; 52(1): 128 - 131.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.